person · Reporting owner

Marrone Pamela G

Disclosed activity across 2 companies

Tapewire entity: 109941
SEC CIK: 0001582885

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
FORUM MARKETS IncATNF · Entity 7020	Director	September 04, 2023	September 06, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

FORUM MARKETS Inc

Report date September 04, 2023 · Filed September 06, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	34,857.019	Reported balance After 2023-09-04 transaction · row 1 1 source row Row 1 · 2023-09-04 · Grant · Acquired 22,388 · Balance 34,857.019 F1: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2033-09-04	Direct	15,000	Reported balance After 2023-09-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-09-04 · Grant · Acquired 15,000 · Balance 15,000 F2: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F3: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.

F2: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.

F3: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MARRONE BIO INNOVATIONS INC

Report date July 12, 2022 · Filed July 14, 2022

Section 16 reporting ended · disclosed 2022-07-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2022-07-12 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-07-12 · Grant · Acquired 195,007 · Balance 2,394,141 F1: Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement"). F2: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. Row 2 · 2022-07-12 · Disposition to issuer · Disposed 2,394,141 · Balance 0 F3: Disposed of pursuant to the Merger Agreement in exchange for 210,684 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
Common StockSEC Table I · non-derivative	IndirectHeld by Florence H. Marrone TOD Pamela G Marrone	Reported balance After 2022-07-12 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2022-07-12 · Disposition to issuer · Disposed 6,442 · Balance 0 F4: Disposed of pursuant to the Merger Agreement in exchange for 566 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-07-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-07-12 · Exercise / conversion · Disposed 195,007 · Balance 0 F5: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. F6: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F7: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2026-08-11	Direct	Reported balance After 2022-07-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-07-12 · Disposition to issuer · Disposed 157,500 · Balance 0 F8: This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was cancelled in the Merger in exchange for 3,870 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44 · Expires 2029-07-16	Direct	Reported balance After 2022-07-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-07-12 · Disposition to issuer · Disposed 500,000 · Balance 0 F9: This option, which provided for vesting in equal monthly installments over 48 months at the rate of 1/48th after the vesting commencement date of July 16, 2019, was assumed by BIOX in the Merger and replaced with an option to purchase 44,000 Ordinary Shares of BIOX for $16.36 per share.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2028-05-30	Direct	Reported balance After 2022-07-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-07-12 · Disposition to issuer · Disposed 560,000 · Balance 0 F10: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of May 3, 2018, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 49,280 Ordinary Shares of BIOX for $18.75 per share.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2023-08-01	Direct	Reported balance After 2022-07-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-07-12 · Disposition to issuer · Disposed 1,911 · Balance 0 F11: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of August 1, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 168 Ordinary Shares of BIOX for $136.36 per share.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.08 · Expires 2023-10-29	Direct	Reported balance After 2022-07-12 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-07-12 · Disposition to issuer · Disposed 63,725 · Balance 0 F11: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of August 1, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 168 Ordinary Shares of BIOX for $136.36 per share. F12: This option, which provided for vesting with respect to 1/4th of the total shares subject to the option on October 29, 2013, and 1/48th of the total shares subject to the option monthly thereafter for 36 months, was assumed by BIOX in the Merger and replaced with an option to purchase 5,607 Ordinary Shares of BIOX for $137.31 per share.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.77 · Expires 2023-11-06	Direct	Reported balance After 2022-07-12 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-07-12 · Disposition to issuer · Disposed 482 · Balance 0 F12: This option, which provided for vesting with respect to 1/4th of the total shares subject to the option on October 29, 2013, and 1/48th of the total shares subject to the option monthly thereafter for 36 months, was assumed by BIOX in the Merger and replaced with an option to purchase 5,607 Ordinary Shares of BIOX for $137.31 per share. F13: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of November 6, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 42 Ordinary Shares of BIOX for $190.57 per share.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.01 · Expires 2023-09-27	Direct	Reported balance After 2022-07-12 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-07-12 · Disposition to issuer · Disposed 84,000 · Balance 0 F14: This option, which provided for vesting over a period of four years with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of September 27, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 7,392 Ordinary Shares of BIOX for $204.66 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement").

F2: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4.

F3: Disposed of pursuant to the Merger Agreement in exchange for 210,684 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.

F4: Disposed of pursuant to the Merger Agreement in exchange for 566 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.

F5: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4.

F6: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock.

F7: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants.

F8: This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was cancelled in the Merger in exchange for 3,870 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.

F9: This option, which provided for vesting in equal monthly installments over 48 months at the rate of 1/48th after the vesting commencement date of July 16, 2019, was assumed by BIOX in the Merger and replaced with an option to purchase 44,000 Ordinary Shares of BIOX for $16.36 per share.

F10: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of May 3, 2018, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 49,280 Ordinary Shares of BIOX for $18.75 per share.

F11: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of August 1, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 168 Ordinary Shares of BIOX for $136.36 per share.

F12: This option, which provided for vesting with respect to 1/4th of the total shares subject to the option on October 29, 2013, and 1/48th of the total shares subject to the option monthly thereafter for 36 months, was assumed by BIOX in the Merger and replaced with an option to purchase 5,607 Ordinary Shares of BIOX for $137.31 per share.

F13: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of November 6, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 42 Ordinary Shares of BIOX for $190.57 per share.

F14: This option, which provided for vesting over a period of four years with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of September 27, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 7,392 Ordinary Shares of BIOX for $204.66 per share.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 04, 2023 Filed Sep 6, 2023 22:24 UTC	FORUM MARKETS Inc ATNF · Entity 7020	GrantNon-Qualified Stock Option (right to buy) · Derivative	15,000	$0.00 Strike: $0.67	$0.00	Disclosure SEC source: 0001213900-23-074480 · ownership.xml · derivative · entry 2 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-09-04 F2 · kind: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F2 · price: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F3 · derivative.exercise_date: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates. Read SEC document
September 04, 2023 Filed Sep 6, 2023 22:24 UTC	FORUM MARKETS Inc ATNF · Entity 7020	GrantCommon Stock	22,388	$0.00	$0.00	Disclosure SEC source: 0001213900-23-074480 · ownership.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,857.019 F1 · kind: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F1 · price: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. Read SEC document
May 18, 2023 Filed May 19, 2023 12:45 UTC	FORUM MARKETS Inc ATNF · Entity 7020	PurchaseCommon Stock	7,082.019	$1.06	$7,506.94	Disclosure SEC source: 0001213900-23-041331 · ownership.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,469.019 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.03 to $1.07, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
October 31, 2022 Filed Nov 2, 2022 21:02 UTC	FORUM MARKETS Inc ATNF · Entity 7020	GrantCommon Stock	32,037	$0.00	$0.00	Disclosure SEC source: 0001213900-22-068722 · ownership.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,170 F1 · kind: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended September 30, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F1 · price: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended September 30, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. Read SEC document
July 27, 2022 Filed Jul 29, 2022 20:18 UTC	FORUM MARKETS Inc ATNF · Entity 7020	GrantCommon Stock	13,636	$0.00	$0.00	Disclosure SEC source: 0001213900-22-042961 · ownership.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,133 F1 · kind: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended June 30, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F1 · price: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended June 30, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. Read SEC document
July 12, 2022 Filed Jul 14, 2022 20:46 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerStock Option (Right to Buy) · Derivative	84,000	Not disclosed Strike: $18.01	Not disclosed	Disclosure SEC source: 0001209191-22-042206 · doc4.xml · derivative · entry 11 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 84,000 shares Expires 2023-09-27 F14 · price: This option, which provided for vesting over a period of four years with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of September 27, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 7,392 Ordinary Shares of BIOX for $204.66 per share. F14 · derivative.exercise_date: This option, which provided for vesting over a period of four years with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of September 27, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 7,392 Ordinary Shares of BIOX for $204.66 per share. Read SEC document
July 12, 2022 Filed Jul 14, 2022 20:46 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerStock Option (Right to Buy) · Derivative	482	Not disclosed Strike: $16.77	Not disclosed	Disclosure SEC source: 0001209191-22-042206 · doc4.xml · derivative · entry 10 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 482 shares Expires 2023-11-06 F12 · price: This option, which provided for vesting with respect to 1/4th of the total shares subject to the option on October 29, 2013, and 1/48th of the total shares subject to the option monthly thereafter for 36 months, was assumed by BIOX in the Merger and replaced with an option to purchase 5,607 Ordinary Shares of BIOX for $137.31 per share. F13 · derivative.exercise_date: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of November 6, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 42 Ordinary Shares of BIOX for $190.57 per share. Read SEC document
July 12, 2022 Filed Jul 14, 2022 20:46 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerStock Option (Right to Buy) · Derivative	63,725	Not disclosed Strike: $12.08	Not disclosed	Disclosure SEC source: 0001209191-22-042206 · doc4.xml · derivative · entry 9 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,725 shares Expires 2023-10-29 F11 · price: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of August 1, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 168 Ordinary Shares of BIOX for $136.36 per share. F12 · derivative.exercise_date: This option, which provided for vesting with respect to 1/4th of the total shares subject to the option on October 29, 2013, and 1/48th of the total shares subject to the option monthly thereafter for 36 months, was assumed by BIOX in the Merger and replaced with an option to purchase 5,607 Ordinary Shares of BIOX for $137.31 per share. Read SEC document
July 12, 2022 Filed Jul 14, 2022 20:46 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerStock Option (Right to Buy) · Derivative	1,911	Not disclosed Strike: $12.00	Not disclosed	Disclosure SEC source: 0001209191-22-042206 · doc4.xml · derivative · entry 8 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,911 shares Expires 2023-08-01 F11 · price: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of August 1, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 168 Ordinary Shares of BIOX for $136.36 per share. F11 · derivative.exercise_date: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of August 1, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 168 Ordinary Shares of BIOX for $136.36 per share. Read SEC document
July 12, 2022 Filed Jul 14, 2022 20:46 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerStock Option (Right to Buy) · Derivative	560,000	Not disclosed Strike: $1.65	Not disclosed	Disclosure SEC source: 0001209191-22-042206 · doc4.xml · derivative · entry 7 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 560,000 shares Expires 2028-05-30 F10 · price: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of May 3, 2018, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 49,280 Ordinary Shares of BIOX for $18.75 per share. F10 · derivative.exercise_date: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of May 3, 2018, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 49,280 Ordinary Shares of BIOX for $18.75 per share. Read SEC document
July 12, 2022 Filed Jul 14, 2022 20:46 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerStock Option (Right to Buy) · Derivative	500,000	Not disclosed Strike: $1.44	Not disclosed	Disclosure SEC source: 0001209191-22-042206 · doc4.xml · derivative · entry 6 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2029-07-16 F9 · price: This option, which provided for vesting in equal monthly installments over 48 months at the rate of 1/48th after the vesting commencement date of July 16, 2019, was assumed by BIOX in the Merger and replaced with an option to purchase 44,000 Ordinary Shares of BIOX for $16.36 per share. F9 · derivative.exercise_date: This option, which provided for vesting in equal monthly installments over 48 months at the rate of 1/48th after the vesting commencement date of July 16, 2019, was assumed by BIOX in the Merger and replaced with an option to purchase 44,000 Ordinary Shares of BIOX for $16.36 per share. Read SEC document
July 12, 2022 Filed Jul 14, 2022 20:46 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerStock Option (Right to Buy) · Derivative	157,500	Not disclosed Strike: $0.80	Not disclosed	Disclosure SEC source: 0001209191-22-042206 · doc4.xml · derivative · entry 5 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 157,500 shares Expires 2026-08-11 F8 · price: This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was cancelled in the Merger in exchange for 3,870 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger. F8 · derivative.exercise_date: This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was cancelled in the Merger in exchange for 3,870 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger. Read SEC document
July 12, 2022 Filed Jul 14, 2022 20:46 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionRestricted Stock Units · Derivative	195,007	$0.00	$0.00	Disclosure SEC source: 0001209191-22-042206 · doc4.xml · derivative · entry 4 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 195,007 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. F6 · derivative.exercise_price: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F5 · shares: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. F7 · shares: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants. F7 · derivative.exercise_date: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants. F7 · derivative.expiration_date: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants. F5 · derivative.underlying_shares: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. F7 · derivative.underlying_shares: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants. Read SEC document
July 12, 2022 Filed Jul 14, 2022 20:46 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerCommon Stock	6,442	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-042206 · doc4.xml · nonDerivative · entry 3 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Florence H. Marrone TOD Pamela G Marrone Disclosed balance after: 0 F4 · price: Disposed of pursuant to the Merger Agreement in exchange for 566 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger. Read SEC document
July 12, 2022 Filed Jul 14, 2022 20:46 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerCommon Stock	2,394,141	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-042206 · doc4.xml · nonDerivative · entry 2 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Disposed of pursuant to the Merger Agreement in exchange for 210,684 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger. Read SEC document
July 12, 2022 Filed Jul 14, 2022 20:46 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	GrantCommon Stock	195,007	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-042206 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,394,141 F1 · shares: Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement"). F2 · shares: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. F1 · price: Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement"). Read SEC document
July 06, 2022 Filed Jul 7, 2022 17:22 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionStock Option (Right to buy) · Derivative	20,000	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0001209191-22-041507 · doc4.xml · derivative · entry 3 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,320 Underlying: Common Stock · 20,000 shares Expires 2026-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested with respect to 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of August 11, 2016, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months. Read SEC document
July 06, 2022 Filed Jul 7, 2022 17:22 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock	20,000	$0.80	$16,000.00	Disclosure SEC source: 0001209191-22-041507 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,199,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 09, 2022 Filed Jun 13, 2022 17:20 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	SaleCommon Stock	20,492	$1.18	$24,121.13	Disclosure SEC source: 0001209191-22-036400 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,179,134 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.15 to $1.21, inclusive. The reporting person undertakes to provide to Marrone Bio Innovations, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
May 24, 2022 Filed May 25, 2022 18:50 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	SaleCommon Stock	21,009	$1.15	$24,118.33	Disclosure SEC source: 0001209191-22-031981 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,199,626 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.10 to $1.19, inclusive. The reporting person undertakes to provide to Marrone Bio Innovations, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
May 19, 2022 Filed May 23, 2022 20:33 UTC	FORUM MARKETS Inc ATNF · Entity 7020	GrantNon-Qualified Stock Option (right to buy) · Derivative	21,000	$0.00 Strike: $1.36	$0.00	Disclosure SEC source: 0001213900-22-028979 · ownership.xml · derivative · entry 2 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-05-19 F2 · kind: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F2 · price: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F3 · derivative.exercise_date: The Options vest at the rate of 1/39th of such options ratably on a monthly basis over the following 39 months following the grant date, on the last day of each calendar month (beginning on May 31, 2022), subject to the holder's continued service to the Company. Read SEC document
May 19, 2022 Filed May 23, 2022 20:33 UTC	FORUM MARKETS Inc ATNF · Entity 7020	GrantCommon Stock	11,030	$1.36	$15,000.80	Disclosure SEC source: 0001213900-22-028979 · ownership.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,497 F1 · kind: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended March 31, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F1 · price: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended March 31, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. Read SEC document
March 24, 2022 Filed Mar 28, 2022 17:40 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionStock Option (Right to buy) · Derivative	20,000	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0001209191-22-021343 · doc4.xml · derivative · entry 4 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,320 Underlying: Common Stock · 20,000 shares Expires 2026-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vested with respect to 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of August 11, 2016, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months. Read SEC document
March 24, 2022 Filed Mar 28, 2022 17:40 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	SaleCommon Stock	22,728	$1.11	$25,228.08	Disclosure SEC source: 0001209191-22-021343 · doc4.xml · nonDerivative · entry 2 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,220,635 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.10 to $1.13, inclusive. The reporting person undertakes to provide to Marrone Bio Innovations, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
March 24, 2022 Filed Mar 28, 2022 17:40 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock	20,000	$0.80	$16,000.00	Disclosure SEC source: 0001209191-22-021343 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,243,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 14, 2022 Filed Jan 18, 2022 21:31 UTC	FORUM MARKETS Inc ATNF · Entity 7020	GrantCommon Stock	2,467	$3.04	$7,499.68	Disclosure SEC source: 0001213900-22-002418 · ownership.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,467 F1 · kind: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended December 31, 2021. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) pursuant to Rule 16b-3. F1 · price: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended December 31, 2021. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) pursuant to Rule 16b-3. Read SEC document
December 10, 2021 Filed Dec 10, 2021 23:39 UTC	FORUM MARKETS Inc ATNF · Entity 7020	PurchaseCommon Stock	1,000	$4.10	$4,100.00	Disclosure SEC source: 0001213900-21-064771 · ownership.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document
October 12, 2021 Filed Jan 25, 2022 17:01 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	GiftCommon Stock	15,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-004825 · doc5.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,223,363 Read SEC document
September 15, 2021 Filed Sep 17, 2021 16:29 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionStock Option (Right to buy) · Derivative	30,000	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0001209191-21-056635 · doc4.xml · derivative · entry 3 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,320 Underlying: Common Stock · 30,000 shares Expires 2026-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested with respect to 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of August 11, 2016, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months. Read SEC document
September 15, 2021 Filed Sep 17, 2021 16:29 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock	30,000	$0.80	$24,000.00	Disclosure SEC source: 0001209191-21-056635 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,238,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 24, 2021 Filed Aug 25, 2021 18:37 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	SaleCommon Stock	24,510	$1.02	$25,000.20	Disclosure SEC source: 0001209191-21-053362 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,208,363 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.00 to $1.03, inclusive. The reporting person undertakes to provide to Marrone Bio Innovations, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
August 09, 2021 Filed Aug 10, 2021 19:19 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	SaleCommon Stock	17,858	$1.45	$25,894.10	Disclosure SEC source: 0001493152-21-019230 · ownership.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,232,873 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.38 to $1.49, inclusive. The reporting person undertakes to provide to Marrone Bio Innovations, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
August 04, 2021 Filed Aug 5, 2021 20:19 UTC	FORUM MARKETS Inc ATNF · Entity 7020	GrantNon-Qualified Stock Option (right to buy · Derivative	79,000	$0.00 Strike: $7.56	$0.00	Disclosure SEC source: 0001213900-21-040520 · ownership.xml · derivative · entry 2 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,000 Underlying: Common Stock · 79,000 shares Expires 2031-08-04 F1 · kind: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) of the Securities Exchange Act of 1934 pursuant to Rule 16b-3 promulgated under the Exchange Act. F1 · price: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) of the Securities Exchange Act of 1934 pursuant to Rule 16b-3 promulgated under the Exchange Act. F2 · derivative.exercise_date: The Options vest at the rate of 1/48th of such options ratably on a monthly basis over the following 48 months following the grant date, on the last day of each calendar month (beginning on August 31, 2021), subject to the holder's continued service to the Company. Read SEC document
July 26, 2021 Filed Jul 28, 2021 16:38 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	SaleCommon Stock	17,858	$1.40	$25,001.20	Disclosure SEC source: 0001209191-21-048435 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250,731 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.38 to $1.43, inclusive. The reporting person undertakes to provide to Marrone Bio Innovations, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes shares that are held jointly with spouse, which were previously reported separately. Read SEC document
July 09, 2021 Filed Jul 12, 2021 18:33 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	SaleCommon Stock	17,007	$1.49	$25,340.43	Disclosure SEC source: 0001209191-21-046335 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,215,455 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.470 to $1.505, inclusive. The reporting person undertakes to provide to Marrone Bio Innovations, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
June 24, 2021 Filed Jun 28, 2021 16:56 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	SaleCommon Stock	13,662	$1.79	$24,454.98	Disclosure SEC source: 0001209191-21-043498 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,232,462 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.755 to $1.8300, inclusive. The reporting person undertakes to provide to Marrone Bio Innovations, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
June 09, 2021 Filed Jun 11, 2021 16:15 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	SaleCommon Stock	15,061	$1.69	$25,453.09	Disclosure SEC source: 0001209191-21-039822 · doc4.xml · nonDerivative · entry 2 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,246,124 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.64 to $1.75, inclusive. The reporting person undertakes to provide to Marrone Bio Innovations, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
May 24, 2021 Filed Jun 11, 2021 16:15 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	SaleCommon Stock	16,892	$1.41	$23,817.72	Disclosure SEC source: 0001209191-21-039822 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,261,185 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.41 to $1.49, inclusive. The reporting person undertakes to provide to Marrone Bio Innovations, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
May 14, 2021 Filed May 17, 2021 16:39 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock	13,807	$1.41	$19,467.87	Disclosure SEC source: 0001209191-21-033177 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,278,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 03, 2021 Filed Feb 5, 2021 18:19 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionRestricted Stock Units · Derivative	22,058	$0.00	$0.00	Disclosure SEC source: 0001209191-21-008271 · doc4.xml · derivative · entry 8 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,058 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F5 · derivative.exercise_date: The restricted stock units vested with respect to 100% of the total shares subject to the grant on October 2, 2019, and the underlying shares were delivered to the reporting person on the first business day following the six-month anniversary of her retirement date in accordance with her separation agreement. F5 · derivative.expiration_date: The restricted stock units vested with respect to 100% of the total shares subject to the grant on October 2, 2019, and the underlying shares were delivered to the reporting person on the first business day following the six-month anniversary of her retirement date in accordance with her separation agreement. Read SEC document
February 03, 2021 Filed Feb 5, 2021 18:19 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionRestricted Stock Units · Derivative	40,704	$0.00	$0.00	Disclosure SEC source: 0001209191-21-008271 · doc4.xml · derivative · entry 7 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,704 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F4 · derivative.exercise_date: The restricted stock units vested with respect to 100% of the total shares subject to the grant on March 25, 2018, and the underlying shares were delivered to the reporting person on the first business day following the six-month anniversary of her retirement date in accordance with her separation agreement. F4 · derivative.expiration_date: The restricted stock units vested with respect to 100% of the total shares subject to the grant on March 25, 2018, and the underlying shares were delivered to the reporting person on the first business day following the six-month anniversary of her retirement date in accordance with her separation agreement. Read SEC document
February 03, 2021 Filed Feb 5, 2021 18:19 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionRestricted Stock Units · Derivative	25,192	$0.00	$0.00	Disclosure SEC source: 0001209191-21-008271 · doc4.xml · derivative · entry 6 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,192 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vested with respect to 100% of the total shares subject to the grant on May 21, 2017, and the underlying shares were delivered to the reporting person on the first business day following the six-month anniversary of her retirement date in accordance with her separation agreement. F3 · derivative.expiration_date: The restricted stock units vested with respect to 100% of the total shares subject to the grant on May 21, 2017, and the underlying shares were delivered to the reporting person on the first business day following the six-month anniversary of her retirement date in accordance with her separation agreement. Read SEC document
February 03, 2021 Filed Feb 5, 2021 18:19 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock	22,058	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-008271 · doc4.xml · nonDerivative · entry 3 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,264,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. Read SEC document
February 03, 2021 Filed Feb 5, 2021 18:19 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock	40,704	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-008271 · doc4.xml · nonDerivative · entry 2 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,242,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. Read SEC document
February 03, 2021 Filed Feb 5, 2021 18:19 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock	25,192	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-008271 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,201,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. Read SEC document
December 08, 2020 Filed Dec 10, 2020 19:05 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionStock Option (right to buy) · Derivative	31,863	$0.00 Strike: $1.19	$0.00	Disclosure SEC source: 0001209191-20-062794 · doc4.xml · derivative · entry 4 Marrone Pamela G · CIK 0001582885 · Director · Consultant 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,863 shares Expires 2021-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vested with respect to 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of January 1, 2011, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months. Read SEC document
December 08, 2020 Filed Dec 10, 2020 19:05 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock	31,863	$1.19	$37,916.97	Disclosure SEC source: 0001209191-20-062794 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director · Consultant 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,176,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The number of securities reported also reflects the acquisition of a total of 30,407 shares of the issuer's common stock pursuant to the issuer's employee stock purchase plan. Read SEC document
August 04, 2020 Filed Aug 5, 2020 19:17 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	GrantCommon Stock	1,250,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-045298 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director · Consultant 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,114,046 F1 · shares: Represents shares subject to restricted stock units, which will vest in equal installments on each of the first three anniversaries of Dr. Marrone's retirement date of August 2, 2020, subject to her continuous service as a consultant through the applicable vesting dates. Read SEC document
July 15, 2020 Filed Jul 21, 2020 19:15 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $0.80	$0.00	Disclosure SEC source: 0001209191-20-043244 · doc4.xml · derivative · entry 4 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2026-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested with respect to 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of August 11, 2016, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months. Read SEC document
July 15, 2020 Filed Jul 21, 2020 19:15 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock	12,500	$0.80	$10,000.00	Disclosure SEC source: 0001209191-20-043244 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 864,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.